GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immuno-therapy Jemperli had shown promise when used in harness with an existing cancer drug, Zejula, when treating advanced or recurrent endometrial forms of the killer disease.
Its RUBY Part 2 phase III trial revealed the combination significantly improved the progression-free survival of patients.
This finding is particularly relevant for a subtype of endometrial cancer known as mismatch repair proficient/microsatellite stable (MMRp/MSS), which traditionally has limited treatment options beyond standard chemotherapy.
While the full data analysis, including overall survival rates, is still ongoing, the initial findings are promising. The safety profile of the drug combination was generally in line with the known profiles of the individual drugs. Detailed results from this study are expected to be presented at an upcoming scientific meeting and published in a medical journal.
Endometrial cancer, which originates in the uterus's inner lining, is the most prevalent gynecologic cancer in developed countries. With rising incidence rates, new and effective treatment options like this combination therapy offer hope to a significant number of patients diagnosed with this challenging condition.
"Patients with MMRp/MSS primary advanced or recurrent endometrial cancer have few approved treatment options," said Hesham Abdullah, GSK's head of oncology R&D.
"Today's positive topline results reinforce our approach of building combination therapies with dostarlimab as the backbone in an effort to improve patient outcomes and options."